Viruses in Rodent Colonies: Lessons Learned from Murine Noroviruses

Annual Review of Virology

Volumn 2, Issue , 2015, Pages 525-548

  Karst, Stephanie M ^a   Wobus, Christiane E ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Animal model; Calicivirus; Enteric virus; Positive sense RNA virus; Virus microbiota host interplay

Indexed keywords

ANTIVIRUS AGENT; CARBOHYDRATE; GLYCAN; INTERFERON; TYPE III INTERFERON; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL VIRUS; ANTIVIRAL THERAPY; B CELL CULTURE; B LYMPHOCYTE; BACTERIUM; COLON FLORA; COMMENSAL; DENDRITIC CELL; DRUG TARGETING; ENDEMIC DISEASE; ENTERIC VIRUS; FECES MICROFLORA; GENETIC CONSERVATION; GERMFREE MOUSE; HELMINTHIASIS; HUMAN; HUMAN NOROVIRUS; HUMAN VERSUS ANIMAL COMPARISON; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; MACROPHAGE; MALNUTRITION; MEDICAL RESEARCH; MIXED INFECTION; MOLECULAR PHYLOGENY; MURINE NOROVIRUS; NONHUMAN; NOROVIRUS; NOROVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; VIRAL PHENOMENA AND FUNCTIONS; VIRAL TROPISM; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS IMMUNITY; VIRUS PATHOGENESIS; VIRUS SHEDDING; VIRUS STRAIN; ANIMAL; CALICIVIRUS INFECTION; GENETICS; MOUSE; PHYSIOLOGY; RODENT DISEASE; VETERINARY; VIROLOGY;

ANIMALS; CALICIVIRIDAE INFECTIONS; HUMANS; MICE; NOROVIRUS; RODENT DISEASES;

EID: 84969132726     PISSN: 2327056X     EISSN: 23270578     Source Type: Journal    
DOI: 10.1146/annurev-virology-100114-055204     Document Type: Review

References (153)

1. Mumphrey SM, Changotra H, Moore TN, Heimann-Nichols ER, Wobus CE, et al. 2007. Murine norovirus 1 infection is associated with histopathological changes in immunocompetent hosts, but clinical disease is prevented by STAT1-dependent interferon responses. J. Virol. 81:3251-63
2. Karst SM, Wobus CE, Lay M, Davidson J, Virgin HWIV. 2003. STAT1-dependent innate immunity to a Norwalk-like virus. Science 299:1575-78
3. Hsu CC, Wobus CE, Steffen EK, Riley LK, Livingston RS. 2005. Development of a microsphere-based serologic multiplexed fluorescent immunoassay and a reverse transcriptase PCR assay to detect murine norovirus 1 infection in mice. Clin. Vaccine Immunol. 12:1145-51
4. Henderson KS. 2008. Murine norovirus, a recently discovered and highly prevalent viral agent of mice. Lab. Anim. 37:314-20
5. Xiang Z, Tian S, Tong W, Chang H, Su J, et al. 2014. MNV primarily surveillance by a recombination VP1-derived ELISA in Beijing area in China. J. Immunol. Methods 408:70-77
6. Mahler M, Kohl W. 2009. A serological survey to evaluate contemporary prevalence of viral agents and Mycoplasma pulmonis in laboratory mice and rats in western Europe. Lab. Anim. 38:161-65
7. Pritchett-Corning KR, Cosentino J, Clifford CB. 2009. Contemporary prevalence of infectious agents in laboratory mice and rats. Lab. Anim. 43:165-73
8. Cadwell K. 2015. Expanding the role of the virome: commensalism in the gut. J. Virol. 89:1951-53
9. Green KY. 2013. Caliciviridae: The noroviruses. In Fields Virology, ed. DM Knipe, PM Howley, pp. 582-608. Philadelphia: LippincottWilliams & Wilkins. 6th ed.
10. Vongpunsawad S, Venkataram Prasad BV, Estes MK. 2013. Norwalk virus minor capsid protein VP2 associates within the VP1 shell domain. J. Virol. 87:4818-25
11. Glass PJ, White LJ, Ball JM, Leparc-Goffart I,Hardy ME, Estes MK. 2000. Norwalk virus open reading frame 3 encodes a minor structural protein. J. Virol. 74:6581-91
12. McFadden N, Bailey D, Carrara G, Benson A, Chaudhry Y, et al. 2011. Norovirus regulation of the innate immune response and apoptosis occurs via the product of the alternative open reading frame 4. PLOS Pathog. 7:e1002413
13. Thackray LB, Wobus CE, Chachu KA, Liu B, Alegre ER, et al. 2007. Murine noroviruses comprising a single genogroup exhibit biological diversity despite limited sequence divergence. J. Virol. 81:10460-73
14. Kroneman A, Vega E, Vennema H, Vinje J, White PA, et al. 2013. Proposal for a unified norovirus nomenclature and genotyping. Arch. Virol. 158:2059-68
15. Vinje J. 2015. Advances in laboratory methods for detection and typing of norovirus. J. Clin. Microbiol. 53:373-81
16. Siebenga JJ, Vennema H, Zheng DP, Vinje J, Lee BE, et al. 2009. Norovirus illness is a global problem: emergence and spread of norovirus GII.4 variants, 2001-2007. J. Infect. Dis. 200:802-12
17. Vega E, Barclay L, GregoricusN, Shirley SH, Lee D, Vinje J. 2014. Genotypic and epidemiologic trends of norovirus outbreaks in the United States, 2009 to 2013. J. Clin. Microbiol. 52:147-55
18. Ahmed SM, Hall AJ, Robinson AE, Verhoef L, Premkumar P, et al. 2014. Global prevalence of norovirus in cases of gastroenteritis: A systematic review and meta-analysis. Lancet. Infect. Dis. 14:725-30
19. Patel MM, Widdowson MA, Glass RI, Akazawa K, Vinje J, Parashar UD. 2008. Systematic literature review of role of noroviruses in sporadic gastroenteritis. Emerg. Infect. Dis. 14:1224-31
20. Hall AJ, Lopman BA, Payne DC, Patel MM, Gastanaduy PA, et al. 2013. Norovirus disease in theUnited States. Emerg. Infect. Dis. 19:1198-205
21. Becker-Dreps S, Bucardo F, Vilchez S, Zambrana LE, Liu L, et al. 2014. Etiology of childhood diarrhea after rotavirus vaccine introduction: A prospective, population-based study in Nicaragua. Pediatr. Infect. Dis. J. 33:1156-63
22. Koo HL, Neill FH, Estes MK, Munoz FM, Cameron A, et al. 2013. Noroviruses: The most common pediatric viral enteric pathogen at a large university hospital after introduction of rotavirus vaccination. J. Pediatr. Infect. Dis. Soc. 2:57-60
23. Hemming M, Rasanen S, Huhti L, Paloniemi M, Salminen M, Vesikari T. 2013. Major reduction of rotavirus, but not norovirus, gastroenteritis in children seen in hospital after the introduction of RotaTeq vaccine into the National Immunization Programme in Finland. Eur. J. Pediatr. 172:739-46
24. Scharff RL. 2010. Health related costs from foodborne illness in the United States. Rep., Produce Saf. Proj, Georgetown Univ., Washington, DC
25. Hoffmann S, Batz MB, Morris JG Jr. 2012. Annual cost of illness and quality-adjusted life year losses in the United States due to 14 foodborne pathogens. J. Food Prot. 75:1292-302
26. Lopman B, Gastanaduy P, Park GW, Hall AJ, Parashar UD, Vinje J. 2012. Environmental transmission of norovirus gastroenteritis. Curr. Opin. Virol. 2:96-102
27. Cannon JL, Papafragkou E, Park GW, Osborne J, Jaykus LA, Vinje J. 2006. Surrogates for the study of norovirus stability and inactivation in the environment: A comparison of murine norovirus and feline calicivirus. J. Food Prot. 69:2761-65
28. Manuel CA, Hsu CC, Riley LK, Livingston RS. 2008. Soiled-bedding sentinel detection of murine norovirus 4. J. Am. Assoc. Lab. Anim. Sci. 47:31-36
29. Teunis PF, Moe CL, Liu P, Miller SE, Lindesmith L, et al. 2008. Norwalk virus: How infectious is it? J. Med. Virol. 80:1468-76
30. Atmar RL, Opekun AR, Gilger MA, Estes MK, Crawford SE, et al. 2014. Determination of the 50% human infectious dose for Norwalk virus. J. Infect. Dis. 209:1016-22
31. Teunis PF, Sukhrie FH, Vennema H, Bogerman J, Beersma MF, Koopmans MP. 2015. Shedding of norovirus in symptomatic and asymptomatic infections. Epidemiol. Infect. 143:1710-17
32. Mathijs E, Stals A, Baert L, Botteldoorn N, Denayer S, et al. 2012. A review of known and hypothetical transmission routes for noroviruses. Food Environ. Virol. 4:131-52
33. Bitler EJ, Matthews JE, Dickey BW, Eisenberg JN, Leon JS. 2013. Norovirus outbreaks: A systematic review of commonly implicated transmission routes and vehicles. Epidemiol. Infect. 141:1563-71
34. Jones MK, Watanabe M, Zhu S, Graves CL, Keyes LR, et al. 2014. Enteric bacteria promote human and mouse norovirus infection of B cells. Science 346:755-59
35. Wobus CE, Karst SM, Thackray LB, Chang KO, Sosnovtsev SV, et al. 2004. Replication of norovirus in cell culture reveals a tropism for dendritic cells and macrophages. PLOS Biol. 2:e432
36. Ward VK, McCormick CJ, Clarke IN, Salim O, Wobus CE, et al. 2007. Recovery of infectious murine norovirus using pol II-driven expression of full-length cDNA. PNAS 104:11050-55
37. Arias A, Urena L, Thorne L, Yunus MA, Goodfellow I. 2012. Reverse genetics mediated recovery of infectious murine norovirus. J. Vis. Exp. 2012:e4145
38. Chaudhry Y, Skinner MA, Goodfellow IG. 2007. Recovery of genetically defined murine norovirus in tissue culture by using a fowlpox virus expressing T7 RNA polymerase. J. Gen. Virol. 88:2091-100
39. Wobus CE, Thackray LB, Virgin HWIV. 2006. Murine norovirus: A model system to study norovirus biology and pathogenesis. J. Virol. 80:5104-12
40. Karst SM, Wobus CE, Goodfellow IG, Green KY, Virgin HW. 2014. Advances in norovirus biology. Cell Host Microbe 15:668-80
41. Thorne LG, Goodfellow IG. 2014. Norovirus gene expression and replication. J. Gen. Virol. 95:278-91
42. Lay MK, Atmar RL, Guix S, Bharadwaj U, He H, et al. 2010. Norwalk virus does not replicate in human macrophages or dendritic cells derived from the peripheral blood of susceptible humans. Virology 406:1-11
43. Papafragkou E,Hewitt J, ParkGW, GreeningG, Vinje J. 2013. Challenges of culturing human norovirus in three-dimensional organoid intestinal cell culture models. PLOS ONE 8:e63485
44. Duizer E, Schwab KJ, Neill FH, Atmar RL, Koopmans MP, Estes MK. 2004. Laboratory efforts to cultivate noroviruses. J. Gen. Virol. 85:79-87
45. Herbst-Kralovetz MM, Radtke AL, Lay MK, Hjelm BE, Bolick AN, et al. 2013. Lack of norovirus replication and histo-blood group antigen expression in 3-dimensional intestinal epithelial cells. Emerg. Infect. Dis. 19:431-38
46. Takanashi S, Saif LJ, Hughes JH, Meulia T, Jung K, et al. 2014. Failure of propagation of human norovirus in intestinal epithelial cells with microvilli grown in three-dimensional cultures. Arch. Virol. 159:257-66
47. Ward JM,Wobus CE,ThackrayLB, ErexsonCR, Faucette LJ, et al. 2006. Pathology of immunodeficient mice with naturally occurring murine norovirus infection. Toxicol. Pathol. 34:708-15
48. Bok K, Prikhodko VG, Green KY, Sosnovtsev SV. 2009. Apoptosis in murine norovirus-infected RAW264.7 cells is associated with downregulation of survivin. J. Virol. 83:3647-56
49. Bok K, Parra GI, MitraT, Abente E, Shaver CK, et al. 2011. Chimpanzees as an animal model for human norovirus infection and vaccine development. PNAS 108:325-30
50. Chan MC, HoWS, Sung JJ. 2011. In vitro whole-virus binding of a norovirus genogroup II genotype 4 strain to cells of the lamina propria and Brunner's glands in the human duodenum. J. Virol. 85:8427-30
51. Taube S, Kolawole AO, Hohne M, Wilkinson JE, Handley SA, et al. 2013. A mouse model for human norovirus. mBio 4:e00450-13
52. Gonzalez-HernandezMB, Liu T, Blanco LP, AubleH, Payne HC,Wobus CE. 2013. Murine norovirus transcytosis across an in vitro polarized murine intestinal epithelial monolayer is mediated by M-like cells. J. Virol. 87:12685-93
53. Gonzalez-Hernandez MB, Liu T, Payne HC, Stencel-Baerenwald JE, Ikizler M, et al. 2014. Efficient norovirus and reovirus replication in the mouse intestine requires microfold (M) cells. J. Virol. 88:6934-43
54. Miller H, Zhang J, Kuolee R, Patel GB, Chen W. 2007. Intestinal M cells: The fallible sentinels? World J. Gastroenterol. 13:1477-86
55. Neutra MR, Frey A, Kraehenbuhl JP. 1996. Epithelial M cells: gateways for mucosal infection and immunization. Cell 86:345-48
56. Basic M, Keubler LM, Buettner M, Achard M, Breves G, et al. 2014. Norovirus triggered microbiotadriven mucosal inflammation in interleukin 10-deficient mice. Inflamm. Bowel Dis. 20:431-43
57. Makino A, Shimojima M, Miyazawa T, Kato K, Tohya Y, Akashi H. 2006. Junctional adhesion molecule 1 is a functional receptor for feline calicivirus. J. Virol. 80:4482-90
58. Taube S, JiangM,Wobus CE. 2010. Glycosphingolipids as receptors for non-enveloped viruses. Viruses 2:1011-49
59. Ruvoen-Clouet N, Belliot G, Le Pendu J. 2013. Noroviruses and histo-blood groups: The impact of common host genetic polymorphisms on virus transmission and evolution. Rev. Med. Virol. 23:355-66
60. Tan M, Jiang X. 2011. Norovirus-host interaction: multi-selections by human histo-blood group antigens. Trends Microbiol. 19:382-88
61. Zakhour M, Ruvoen-Clouet N, Charpilienne A, Langpap B, Poncet D, et al. 2009. The αGal epitope of the histo-blood group antigen family is a ligand for bovine norovirus Newbury2 expected to prevent cross-species transmission. PLOS Pathog. 5:e1000504
62. Caddy S, Breiman A, Le Pendu J, Goodfellow I. 2014. Genogroup IV and VI canine noroviruses interact with histo-blood group antigens. J. Virol. 88:10377-91
63. Singh BK, Glatt S, Ferrer JL, Koromyslova AD, Leuthold MM, et al. 2014. Structural analysis of a feline norovirus protruding domain. Virology 474:181-85
64. Tamura M, Natori K, KobayashiM,MiyamuraT,TakedaN. 2004. Genogroup II noroviruses efficiently bind to heparan sulfate proteoglycan associated with the cellular membrane. J. Virol. 78:3817-26
65. Rydell GE,Nilsson J, Rodriguez-Diaz J, Ruvoen-ClouetN, Svensson L, et al. 2009. Human noroviruses recognize sialyl Lewis x neoglycoprotein. Glycobiology 19:309-20
66. Bally M, Rydell GE, Zahn R, Nasir W, Eggeling C, et al. 2012. Norovirus GII.4 virus-like particles recognize galactosylceramides in domains of planar supported lipid bilayers. Angew. Chem. Int. Ed. Engl. 51:12020-24
67. Taube S, Perry JW,McGreevy E, Yetming K, Perkins C, et al. 2012. Murine noroviruses bind glycolipid and glycoprotein attachment receptors in a strain-dependent manner. J. Virol. 86:5584-93
68. Taube S, Perry JW, Yetming K, Patel SP, Auble H, et al. 2009. Ganglioside-linked terminal sialic acid moieties on murine macrophages function as attachment receptors for murine noroviruses. J. Virol. 83:4092-101
69. TanM, Jiang X. 2014. Histo-blood group antigens: A common niche for norovirus and rotavirus. Expert Rev. Mol. Med. 16:e5
70. Taube S, Rubin JR, Katpally U, Smith TJ, Kendall A, et al. 2010. High-resolution X-ray structure and functional analysis of the murine norovirus 1 capsid protein protruding domain. J. Virol. 84:5695-705
71. Kolawole AO, Li M, Xia C, Fischer AE, Giacobbi NS, et al. 2014. Flexibility in surface-exposed loops in a virus capsid mediates escape from antibody neutralization. J. Virol. 88:4543-57
72. Chen Z, Sosnovtsev SV, Bok K, Parra GI, Makiya M, et al. 2013. Development ofNorwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis. J. Virol. 87:9547-57
73. Le Pendu J. 2004. Histo-blood group antigen and human milk oligosaccharides: genetic polymorphism and risk of infectious diseases. Adv. Exp. Med. Biol. 554:135-43
74. Guix S, Asanaka M, Katayama K, Crawford SE, Neill FH, et al. 2007. Norwalk virus RNA is infectious in mammalian cells. J. Virol. 81:12238-48
75. Rydell GE, Dahlin AB, Hook F, Larson G. 2009. QCM-D studies of human norovirus VLPs binding to glycosphingolipids in supported lipid bilayers reveal strain-specific characteristics. Glycobiology 19:1176-84
76. Rydell GE, Svensson L, Larson G, Johannes L, Romer W. 2013. Human GII.4 norovirus VLP induces membrane invaginations on giant unilamellar vesicles containing secretor gene dependent α1,2-fucosylated glycosphingolipids. Biochim. Biophys. Acta 1828:1840-45
77. Oriol R, Le Pendu J, Sparkes RS, SparkesMC, CristM, et al. 1981. Insights into the expression of ABH and Lewis antigens through human bone marrow transplantation. Am. J. Hum. Genet. 33:551-60
78. Wilks J, Golovkina T. 2012. Influence of microbiota on viral infections. PLOS Pathog. 8:e1002681
79. Robinson CM, Pfeiffer JK. 2014. Viruses and the microbiota. Annu. Rev. Virol. 1:55-69
80. Kuss SK, Best GT, Etheredge CA, Pruijssers AJ, Frierson JM, et al. 2011. Intestinal microbiota promote enteric virus replication and systemic pathogenesis. Science 334:249-52
81. Kane M, Case LK, Kopaskie K, Kozlova A, MacDearmid C, et al. 2011. Successful transmission of a retrovirus depends on the commensal microbiota. Science 334:245-49
82. Uchiyama R, Chassaing B, Zhang B, Gewirtz AT. 2014. Antibiotic treatment suppresses rotavirus infection and enhances specific humoral immunity. J. Infect. Dis. 210:171-82
83. Robinson CM, Jesudhasan PR, Pfeiffer JK. 2014. Bacterial lipopolysaccharide binding enhances virion stability and promotes environmental fitness of an enteric virus. Cell Host Microbe 15:36-46
84. Baldridge MT, Nice TJ,McCune BT, Yokoyama CC, Kambal A, et al. 2015. Commensal microbes and interferon-λ determine persistence of enteric murine norovirus infection. Science 347:266-69
85. Kernbauer E,Ding Y,Cadwell K. 2014. An enteric virus can replace the beneficial function of commensal bacteria. Nature 516:94-98
86. Miura T, Sano D, Suenaga A, Yoshimura T, Fuzawa M, et al. 2013. Histo-blood group antigen-like substances of human enteric bacteria as specific adsorbents for human noroviruses. J. Virol. 87:9441-51
87. Karst SM, Wobus CE. 2015. A working model of how noroviruses infect the intestine. PLOS Pathog. 11:e1004626
88. Atmar RL, Opekun AR, Gilger MA, Estes MK, Crawford SE, et al. 2008. Norwalk virus shedding after experimental human infection. Emerg. Infect. Dis. 14:1553-57
89. Murata T, Katsushima N, Mizuta K, Muraki Y, Hongo S, Matsuzaki Y. 2007. Prolonged norovirus shedding in infants ≤6 months of age with gastroenteritis. Pediatr. Infect. Dis. J. 26:46-49
90. Bok K, Green KY. 2012. Norovirus gastroenteritis in immunocompromised patients. N. Engl. J. Med. 367:2126-32
91. Siebenga JJ, Beersma MF, Vennema H, van Biezen P,Hartwig NJ, KoopmansM. 2008. High prevalence of prolonged norovirus shedding and illness among hospitalized patients: A model for in vivo molecular evolution. J. Infect. Dis. 198:994-1001
92. Bull RA, Eden JS, Luciani F, McElroy K, RawlinsonWD, White PA. 2012. Contribution of intra-and interhost dynamics to norovirus evolution. J. Virol. 86:3219-29
93. Arias A, Bailey D, Chaudhry Y, Goodfellow I. 2012. Development of a reverse-genetics system for murine norovirus 3: Long-term persistence occurs in the caecum and colon. J. Gen. Virol. 93:1432-41
94. Nice TJ, Strong DW, McCune BT, Pohl CS, Virgin HW. 2013. A single-amino-acid change in murine norovirus NS1/2 is sufficient for colonic tropism and persistence. J. Virol. 87:327-34
95. Tomov VT, Osborne LC, Dolfi DV, Sonnenberg GF, Monticelli LA, et al. 2013. Persistent enteric murine norovirus infection is associated with functionally suboptimal virus-specificCD8Tcell responses. J. Virol. 87:7015-31
96. Nice TJ, Baldridge MT,McCune BT, Norman JM,LazearHM,et al. 2014. Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity. Science 347:269-73
97. Haque R, Snider C, Liu Y, Ma JZ, Liu L, et al. 2014. Oral polio vaccine response in breast fed infants with malnutrition and diarrhea. Vaccine 32:478-82
98. Qadri F, Bhuiyan TR, Sack DA, Svennerholm AM. 2013. Immune responses and protection in children in developing countries induced by oral vaccines. Vaccine 31:452-60
99. von Bubnoff A. 2011. A gut response to vaccines. IAVI Rep. 15:12-14
100. Beck MA, Handy J, Levander OA. 2004. Host nutritional status: The neglected virulence factor. Trends Microbiol. 12:417-23
101. Hickman D, Jones MK, Zhu S, Kirkpatrick E, Ostrov DA, et al. 2014. The effect of malnutrition on norovirus infection. mBio 5:e01032-13
102. Osborne LC, Monticelli LA, Nice TJ, Sutherland TE, Siracusa MC, et al. 2014. Virus-helminth coinfection reveals a microbiota-independent mechanism of immunomodulation. Science 345:578-82
103. Chang KO, Sosnovtsev SV, Belliot G, King AD, Green KY. 2006. Stable expression of a Norwalk virus RNA replicon in a human hepatoma cell line. Virology 353:463-73
104. Arias A, Emmott E, Vashist S, Goodfellow I. 2013. Progress towards the prevention and treatment of norovirus infections. Future Microbiol. 8:1475-87
105. Rocha-Pereira J, Neyts J, Jochmans D. 2014. Norovirus: targets and tools in antiviral drug discovery. Biochem. Pharmacol. 91:1-11
106. Zeitler CE, Estes MK, Venkataram Prasad BV. 2006. X-ray crystallographic structure of the Norwalk virus protease at 1.5-A resolution. J. Virol. 80:5050-58
107. Ng KK, Pendas-Franco N, Rojo J, Boga JA, Machin A, et al. 2004. Crystal structure of Norwalk virus polymerase reveals the carboxyl terminus in the active site cleft. J. Biol. Chem. 279:16638-45
108. Rocha-Pereira J, Jochmans D, Dallmeier K, Leyssen P, Cunha R, et al. 2012. Inhibition of norovirus replication by the nucleoside analogue 2'-C-methylcytidine. Biochem. Biophys. Res. Commun. 427:796-800
109. Costantini VP,Whitaker T, Barclay L, Lee D,McBrayer TR, et al. 2012. Antiviral activity of nucleoside analogues against norovirus. Antivir. Ther. 17:981-91
110. Rocha-Pereira J, Jochmans D, Debing Y, Verbeken E, Nascimento MS, Neyts J. 2013. The viral polymerase inhibitor 2'-C-methylcytidine inhibits Norwalk virus replication and protects against norovirusinduced diarrhea and mortality in a mouse model. J. Virol. 87:11798-805
111. Rocha-Pereira J, Jochmans D, Neyts J. 2015. Prophylactic treatment with the nucleoside analogue 2'-C-methylcytidine completely prevents transmission of norovirus. J. Antimicrob. Chemother. 70:190-97
112. Toniutto P, Fabris C, Bitetto D, Fornasiere E, Rapetti R, Pirisi M. 2007. Valopicitabine dihydrochloride: A specific polymerase inhibitor of hepatitis C virus. Curr. Opin. Investig. Drugs 8:150-58
113. Lopatto E, Zimm A. 2007. Novartis, Idenix suspend tests on hepatitis C drug NM283. Hepat. C Artic. 3630, Nat. AIDS Treat. Advocacy Proj. (NATAP), New York, NY. http://www.natap.org/2007/HCV/071607-03.htm
114. Sidwell RW, Barnard DL, Day CW, Smee DF, Bailey KW, et al. 2007. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob. Agents Chemother. 51:845-51
115. Gowen BB, Wong MH, Jung KH, Sanders AB, Mendenhall M, et al. 2007. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother. 51:3168-76
116. Morrey JD, Taro BS, Siddharthan V, Wang H, Smee DF, et al. 2008. Efficacy of orally administered T-705 pyrazine analog on lethalWest Nile virus infection in rodents. Antivir. Res. 80:377-79
117. Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS. 2014. Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model. Antivir. Res. 104:153-55
118. Rocha-Pereira J, Jochmans D, Dallmeier K, Leyssen P, Nascimento MS, Neyts J. 2012. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem. Biophys. Res. Commun. 424:777-80
119. Arias A, Thorne L, Goodfellow I. 2014. Favipiravir elicits antiviral mutagenesis during virus replication in vivo. eLife 3:e03679
120. Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J. 2013. The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5'-triphosphate towards influenza A virus polymerase. PLOS ONE 8:e68347
121. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. 2013. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir. Res. 100:446-54
122. Kapuria V, Peterson LF, Fang D, Bornmann WG, Talpaz M, Donato NJ. 2010. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res. 70:9265-76
123. Perry JW, Ahmed M, Chang KO, Donato NJ, Showalter HD, Wobus CE. 2012. Antiviral activity of a small molecule deubiquitinase inhibitor occurs via induction of the unfolded protein response. PLOS Pathog. 8:e1002783
124. Hayashimoto N, Morita H, Ishida T, Uchida R, Tanaka M, et al. 2015. Microbiological survey of mice (Mus musculus) purchased from commercial pet shops in Kanagawa and Tokyo, Japan. Exp. Anim. 64:155-60
125. Kastenmayer RJ, Perdue KA, ElkinsWR. 2008. Eradication of murine norovirus from a mouse barrier facility. J. Am. Assoc. Lab. Anim. Sci. 47:26-30
126. Larsson E, Tremaroli V, Lee YS, Koren O, Nookaew I, et al. 2012. Analysis of gut microbial regulation of host gene expression along the length of the gut and regulation of gut microbial ecology through MyD88. Gut 61:1124-31
127. Paik J, Fierce Y, Mai PO, Phelps SR,McDonald T, et al. 2011. Murine norovirus increases atherosclerotic lesion size and macrophages in Ldlr-/- mice. Comp. Med. 61:330-38
128. Paik J, Fierce Y, Drivdahl R, Treuting PM, Seamons A, et al. 2010. Effects ofmurine norovirus infection on a mouse model of diet-induced obesity and insulin resistance. Comp. Med. 60:189-95
129. Lencioni KC, Drivdahl R, Seamons A, Treuting PM, Brabb T, Maggio-Price L. 2011. Lack of effect of murine norovirus infection on a mouse model of bacteria-induced colon cancer. Comp. Med. 61:219-26
130. Compton SR, Paturzo FX, Macy JD. 2010. Effect of murine norovirus infection on mouse parvovirus infection. J. Am. Assoc. Lab. Anim. Sci. 49:11-21
131. Hensley SE, Pinto AK, Hickman HD, Kastenmayer RJ, Bennink JR, et al. 2009. Murine norovirus infection has no significant effect on adaptive immunity to vaccinia virus or influenza A virus. J. Virol. 83:7357-60
132. Doom CM, Turula HM, Hill AB. 2009. Investigation of the impact of the common animal facility contaminant murine norovirus on experimental murine cytomegalovirus infection. Virology 392:153-61
133. Ammann CG,MesserRJ, Varvel K, Debuysscher BL, Lacasse RA, et al. 2009. Effects of acute and chronic murine norovirus infections on immune responses and recovery from Friend retrovirus infection. J. Virol. 83:13037-41
134. Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, et al. 2007. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet. 39:207-11
135. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, et al. 2007. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat. Genet. 39:596-604
136. Cadwell K, Patel KK, KomatsuM, VirginHWIV, Stappenbeck TS. 2009. A common role for Atg16L1, Atg5 and Atg7 in small intestinal Paneth cells and Crohn disease. Autophagy 5:250-52
137. Cadwell K, Liu JY, Brown SL, MiyoshiH, Loh J, et al. 2008. A key role for autophagy and the autophagy gene Atg16L1 in mouse and human intestinal Paneth cells. Nature 456:259-63
138. Cadwell K. 2010. Crohn's disease susceptibility gene interactions, a NOD to the newcomer ATG16L1. Gastroenterology 139:1448-50
139. CadwellK, StappenbeckTS, VirginHW. 2009. Role of autophagy and autophagy genes in inflammatory bowel disease. Curr. Top. Microbiol. Immunol. 335:141-67
140. Lencioni KC, Seamons A,Treuting PM, Maggio-Price L, BrabbT. 2008. Murine norovirus: An intercurrent variable in a mouse model of bacteria-induced inflammatory bowel disease. Comp. Med. 58:522-33
141. Hsu CC, Paik J, Treuting PM, Seamons A, Meeker SM, et al. 2014. Infection with murine norovirus 4 does not alter Helicobacter-induced inflammatory bowel disease in Il10-/-mice. Comp. Med. 64:256-63
142. Higgins PD, Johnson LA, Sauder K, Moons D, Blanco L, et al. 2011. Transient or persistent norovirus infection does not alter the pathology of Salmonella typhimurium induced intestinal inflammation and fibrosis in mice. Comp. Immunol. Microbiol. Infect. Dis. 34:247-57
143. Abt MC, Artis D. 2009. The intestinal microbiota in health and disease: The influence of microbial products on immune cell homeostasis. Curr. Opin. Gastroenterol. 25:496-502
144. Brestoff JR, Artis D. 2013. Commensal bacteria at the interface of host metabolism and the immune system. Nat. Immunol. 14:676-84
145. Kau AL, Ahern PP, Griffin NW,Goodman AL,Gordon JI. 2011. Human nutrition, the gut microbiome and the immune system. Nature 474:327-36
146. Nelson AM, Elftman MD, Pinto AK, Baldridge M, Hooper P, et al. 2013. Murine norovirus infection does not cause major disruptions in the murine intestinal microbiota. Microbiome 1:7
147. Nelson AM, Walk ST, Taube S, Taniuchi M, Houpt ER, et al. 2012. Disruption of the human gut microbiota following norovirus infection. PLOS ONE 7:e48224
148. Power SE, O'Toole PW, Stanton C, Ross RP, Fitzgerald GF. 2014. Intestinal microbiota, diet and health. Br. J. Nutr. 111:387-402
149. Schippa S, Conte MP. 2014. Dysbiotic events in gut microbiota: impact on human health. Nutrients 6:5786-805
150. Cao S, Lou Z, Tan M, Chen Y, Liu Y, et al. 2007. Structural basis for the recognition of blood group trisaccharides by norovirus. J. Virol. 81:5949-57
151. Hao N, Chen Y, Xia M, Tan M, Liu W, et al. 2015. Crystal structures of GI.8 Boxer virus P dimers in complex with HBGAs, a novel evolutionary path selected by the Lewis epitope. Protein Cell 6:101-16
152. Sievers F,Wilm A, Dineen D, Gibson TJ,Karplus K, et al. 2011. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 7:539
153. Shanker S, Czako R, Sankaran B, Atmar RL, Estes MK, Prasad BV. 2014. Structural analysis of determinants of histo-blood group antigen binding specificity in genogroup I noroviruses. J. Virol. 88:6168-80